Brad Haverkos
University of Colorado, Denver
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Brad Haverkos as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:30 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04535102 · POLA+BR for Relapsed or Refractory DLBCLUniversity of Colorado, Denver · withdrawn · Diffuse Large B Cell Lymphoma · principal investigator
- Ph1NCT04234048 · Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaSciTech Development, Inc. · recruiting · T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma · principal investigator
- Ph1/Ph2NCT03586999 · Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell LymphomasUniversity of Colorado, Denver · completed · Peripheral T Cell Lymphoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:30 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Genomics Shared ResourceP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · fiscal years 2009 to 2026Named on NCT04535102
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:30 UTC. The ranking covers the 200 most relevant of 6 PubMed records, and a shared surname and initials can bring in a namesake. All 6 on PubMed
- Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study.Blood Adv · 202344 citationsRCR 4.2
- Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.Haematologica · 202435 citationsRCR 4.4
- Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.Br J Haematol · 202319 citationsRCR 1.7
- An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor.Bone Marrow Transplant · 20145 citationsRCR 0.2
- Frontline chemoimmunotherapy with nivolumab and dose-adjusted EPOCH in peripheral T-cell lymphoma: a phase 1 trial.Blood Adv · 20244 citationsRCR 0.7